CoChat

Gastrointestinal Complications of Transplant Immunosuppression

Helderman, J. Harold, Goral, Simin · 2002 · Journal of the American Society of Nephrology
Cited by 224

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Abstract

At a time when the judicious use of a broad range of immunosuppressive drugs has ensured excellent patient and organ survival rates after kidney transplantation, attention is focusing on strategies to minimize their side effects. Almost all immunosuppressive medications are associated with some form of gastrointestinal (GI) complication (1–6). The majority of these complications fall into one of several general categories: infections, mucosal injury and ulceration, biliary tract diseases, diverticular disease, pancreatitis, and malignancy (Table 1). Table 1: Gastrointestinal complications after transplantationAn understanding of the GI morbidities related to transplantation permits the development of systematic strategies to reduce and manage these disorders. In this article, we provide an overview of the GI complications arising from the use of immunosuppressive medications and review common prophylactic and treatment approaches. Infections By suppressing the body’s defensive immune functions, all immunosuppressive regimens can lead to increased rates of systemic or localized infections including those of the GI tract. These infections may be bacterial, viral, fungal, or parasitic and may infect one or more gut segments between the mouth and anus. The following discussion is not intended to be comprehensive but will instead indicate those representative infectious entities that most commonly affect transplant recipients. Viral Infections Infections with cytomegalovirus (CMV) and herpes viruses are very common in transplant recipients. They are very costly and can cause significant morbidity and mortality. We are not going to discuss some other viruses, such as adenoviruses, respiratory syncytial virus, influenza virus, and polyoma virus, which can cause serious infections in the immunocompromised host, because GI involvement with these viruses is not common. CMV Infection. CMV infection occurs in a large proportion of transplant patients and is the most common viral cause of clinical disorders in these patients. The incidence of enteric and/or gastric infection is remarkably high, affecting a substantial portion of patients, especially during the first 6 to 12 mo after organ transplantation. Sakr et al. (7) studied 140 liver transplant recipients before and after transplantation for the presence and the absence of CMV enteritis. They demonstrated that, although only one patient had evidence of enteric CMV infection before transplant, the incidence of CMV enteritis posttransplant was 27.7% in the cyclosporine (CsA)–treated group and 20% in the tacrolimus-treated group. Interestingly, patients treated with tacrolimus in this particular study had less severe enteric CMV infection compared with CsA-treated patients. CMV-related infections may be systemic, in which case patients typically present with viremia and constitutional symptoms and almost always with accompanying leukopenia; they may be localized or tissue-invasive. CMV can affect any segment of the GI tract. The symptoms and signs depend on the affected gut segment and may include dysphagia, odynophagia, nausea, vomiting, abdominal pain, GI bleeding, perforation, or diarrhea. CMV infection can also mimic many other entities such as ischemic colitis, intestinal pseudo-obstruction, toxic megacolon, and colon carcinoma (8). Pancreatitis, especially in recipients of CMV-positive pancreatic allografts, has also been reported (9). If we look at individual immunosuppressive drugs in detail, it was suggested by several studies that there is an association between mycophenolate mofetil (MMF) and tissue-invasive CMV, especially of the GI tract (6,10). All three pivotal MMF trials reported information on increase in tissue-invasive CMV infection without specific reference to the GI tract (6,11,12). In the US trial, tissue-invasive CMV disease was more common in the MMF groups, with rates of 7% for azathioprine (AZA) group, 11% for MMF 2 g/d, and 12% for MMF 3 g/d (11). Serious GI events appeared to be more common in the two smaller MMF studies, but interpretation requires a more detailed analysis of the raw data (10,13). In one study, 57% of patients treated with MMF had either dose reductions or interruptions due to adverse events, especially diarrhea, nausea, vomiting, and leukopenia (13). In addition, 6.5% of patients discontinued medication because of noninfectious GI events, and 6.5% were diagnosed with tissue-invasive CMV of the GI tract, compared with 0% for the AZA group. In the other study reported by Hebert et al. (10), 21% of patients had gastritis, duodenitis, or esophagitis, and 11% had either duodenal or esophageal ulceration. In the same study, CMV disease of the GI tract developed in 11% (2 of 19 patients) after they started receiving MMF. However, as both of these small studies were of graft rescue in refractory acute rejection with high-dose steroid use, higher rates of adverse events are not unexpected. Patients in graft rescue trials tend to

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1681/asn.v131277

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 224

Metadata

Authors
Helderman, J. H., & Goral, S.
Venue
Journal of the American Society of Nephrology
Published
2002-01
Volume
13
Issue
1
Pages
277-287
ISSN
1046-6673 (ISSN-L)
OpenAlex
W2165796728
Cited by
224
References
1
FWCI
4.75
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Gastrointestinal Complications of Transplant Immunosuppression. https://app.cochat.ai/papers/10.1681/asn.v131277
The paper
Helderman, J. H., & Goral, S. (2002). Gastrointestinal Complications of Transplant Immunosuppression. Journal of the American Society of Nephrology. https://doi.org/10.1681/asn.v131277

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.